Interestingly, N17 H-Ras did not suppress myelopoiesis in the bone marrow, yet it greatly attenuated BCR/ABL-induced chronic myelogenous leukemia (CML)-like myeloproliferative disease. Here, HRAS is linked to chronic myelogenous leukemia, BCR-ABL1 positive.